Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
CONTEXT: Meta-analyses of clinical studies have suggested an increased incidence of peripheral fractures in postmenopausal women with type 2 diabetes mellitus taking pioglitazone. The mechanism behind this apparent increase is unknown. OBJECTIVE: The objective of the study was to examine the effects of pioglitazone on bone mineral density (BMD) and turnover. DESIGN AND SETTING: Twenty-five sites (in the United States) enrolled participants in this randomized, double-blind, placebo-controlled study. PARTICIPANTS: Postmenopausal women (n = 156) with impaired fasting glucose or impaired glucose tolerance participated in the study. INTERVENTIONS: The intervention consisted of pioglitazone 30 mg/d (n = 78) or placebo (n = 78), increased to 45 mg/d after 1 month, for 12 months of treatment total, followed by 6 months of washout/follow-up. MAIN OUTCOME MEASURES: Percentage changes from baseline to month 12 and from month 12 to month18 in BMD in total proximal femur (primary end point), total body, femoral neck, lumbar spine, and radius were measured. RESULTS: Least squares mean changes from baseline to month 12 in total proximal femur BMD were -0.69% for pioglitazone and -0.14% for placebo (P = .170). No statistically significant between-group differences were observed for any BMD or bone remodeling marker end point. We observed improved glycemic control and insulin sensitivity with pioglitazone treatment. In addition, pioglitazone appeared to increase body fat, which may affect bone density measurements, especially in the lumbar spine. One pioglitazone-treated and three placebo-treated women experienced confirmed fractures. Over 18 months, one pioglitazone-treated (1.3%) and eight placebo-treated women (10.3%) developed overt type 2 diabetes mellitus. The pattern and incidence of adverse events with pioglitazone were consistent with clinical experience with thiazolidinediones. CONCLUSIONS: Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mechanism is uncertain, and studies have not shown a consistent effect of the drug on bone density.44,45”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [45]
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
PPAR-γ regulates osteoclastogenesis in mice
Wan, Y., Chong, L.-W., & Evans, R. M. (2007) · Nature Medicine · doi:10.1038/nm1672 · Cited by 517
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka-Czernik, B. (2004) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 454
Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation
Ali, A. A., Weinstein, R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444
Reid, I. R. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.3.779 · Cited by 421
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2646 · Cited by 401
Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey
Forsén, L., Meyer, H. E., Midthjell, K., & Edna, T.-H. (1999) · Diabetologia · doi:10.1007/s001250051248 · Cited by 381
Reid, I. R. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.027 · Cited by 367
Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone
Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., & Lecka-Czernik, B. (2007) · Endocrinology · doi:10.1210/en.2006-1587 · Cited by 302
Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B. R., Kliewer, S. A., Lehmann, J. M., & Morris, D. C. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09536-7 · Cited by 295
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Shen, W., Chen, J., Punyanitya, M., Shapses, S., Heshka, S., & Heymsfield, S. B. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0285-9 · Cited by 253
Dormandy, J., Bhattacharya, M., & van Troostenburg de Bruyn, A.-R. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
In Vitro and in Vivo Effects of Adiponectin on Bone
Williams, G. A., Wang, Y., Callon, K. E., Watson, M., Lin, J.-M., Lam, J. B. B., Costa, J. L., Orpe, A., Broom, N., Naot, D., et al. (2009) · Endocrinology · doi:10.1210/en.2008-1639 · Cited by 220
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
Sorocéanu, M. A., Miao, D., Bai, X.-Y., Su, H., Goltzman, D., & Karaplis, A. C. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05723 · Cited by 199
Zinman, B., Haffner, S. M., Herman, W. H., Holman, R. R., Lachin, J. M., Kravitz, B. G., Paul, G., Jones, N. P., Aftring, R. P., Viberti, G., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0572 · Cited by 180
Sottile, V., Seuwen, K., & Kneissel, M. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0224-8 · Cited by 178
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01225.x · Cited by 135
Glintborg, D., Andersen, M., Hagen, C., Heickendorff, L., & Hermann, A. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2249 · Cited by 133
Adiponectin Inhibits Osteoclastogenesis and Bone Resorption via APPL1-mediated Suppression of Akt1
Tu, Q., Zhang, J., Dong, L. Q., Saunders, E., Luo, E., Tang, J., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152405 · Cited by 122
Benvenuti, S., Cellai, I., Luciani, P., Deledda, C., Baglioni, S., Giuliani, C., Saccardi, R., Mazzanti, B., Pozzo, S. D., Mannucci, E., et al. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03350807 · Cited by 122
Berberoglu, Z., Gursoy, A., Bayraktar, N., Yazici, A. C., Bascil Tutuncu, N., & Guvener Demirag, N. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0431 · Cited by 108
Diabetes and fractures: an overshadowed association
Khazai, N. B., Beck, G. R., & Umpierrez, G. E. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328331c7eb · Cited by 106
Bilezikian, J. P., Josse, R. G., Eastell, R., Lewiecki, E. M., Miller, C. G., Wooddell, M., Northcutt, A. R., Kravitz, B. G., Paul, G., Cobitz, A. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4018 · Cited by 99
An overlying fat panniculus affects femur bone mass measurement
Binkley, N., Krueger, D., & Vallarta-Ast, N. (2003) · Journal of Clinical Densitometry · doi:10.1385/jcd:6:3:199 · Cited by 90
Kyle, K., Willett, T. L., Baggio, L. L., Drucker, D. J., & Grynpas, M. D. (2010) · Endocrinology · doi:10.1210/en.2010-1098 · Cited by 82
Adiponectin and bone mass density: The InCHIANTI study
Napoli, N., Pedone, C., Pozzilli, P., Lauretani, F., Ferrucci, L., & Incalzi, R. A. (2010) · Bone · doi:10.1016/j.bone.2010.08.010 · Cited by 74
The effects of adiponectin and leptin on changes in bone mineral density
Study, T. H. A., Barbour, K. E., Zmuda, J. M., Boudreau, R., Strotmeyer, E. S., Horwitz, M. J., Evans, R. W., Kanaya, A. M., Harris, T. B., & Cauley, J. A. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1768-x · Cited by 67
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Leahy, J. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70035-0 · Cited by 67
Rosiglitazone Decreases Bone Mass and Bone Marrow Fat
Harsløf, T., Wamberg, L., Møller, L., Stødkilde-Jørgensen, H., Ringgaard, S., Pedersen, S. B., & Langdahl, B. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2077 · Cited by 57
Diabetes drug pioglitazone (Actos): risk of fracture
Meymeh, R. H., & Wooltorton, E. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.071177 · Cited by 52
Gruntmanis, U., Fordan, S., Ghayee, H. K., Abdullah, S. M., See, R., Ayers, C. R., & McGuire, D. K. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9352-5 · Cited by 49
Cross-Sectional Evidence of a Signaling Pathway from Bone Homeostasis to Glucose Metabolism
Gravenstein, K. S., Napora, J. K., Short, R. G., Ramachandran, R., Carlson, O. D., Metter, E. J., Ferrucci, L., Egan, J. M., & Chia, C. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2589 · Cited by 46
Effect of fat on measurement of bone mineral density.
Javed, F., Yu, W. Y.-H., Thornton, J., & Colt, E. W. D. (2009) · PubMed · Cited by 45
Berberoglu, Z., Yazici, A. C., & Demirag, N. G. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03784.x · Cited by 44
Schinner, S. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79452-x · Cited by 38
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
(2011) · New England Journal of Medicine · doi:10.1056/nejmx110058 · Cited by 34
Distal upper and lower limb fractures associated with thiazolidinedione use.
Jones, S. G., Momin, S. R., Good, M. W., Shea, T. K., & Patric, K. (2009) · PubMed · Cited by 30
Risk of Fracture with Thiazolidinediones: Disease or Drugs?
Bazelier, M. T., Vestergaard, P., Gallagher, A. M., van Staa, T.-P., Cooper, C., Leufkens, H. G. M., & de Vries, F. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9591-8 · Cited by 28
Köroğlu, B. K., Kiris, F., Ersoy, İ. H., Sütçü, R., Yildiz, M., Aksu, O., Ermış, F., Ersoy, S., & Tamer, M. N. (2011) · PubMed · Cited by 26
Tsirella, E., Mavrakanas, T. A., Rager, O., Tsartsalis, S., Kallaras, K., Kokkas, B., & Mironidou‐Tzouveleki, M. (2012) · PubMed · Cited by 18
Τέντα, Ρ., Kontogianni, M. D., & Yiannakouris, N. (2012) · PubMed · doi:10.3275/7744 · Cited by 17
Wu, S., Wu, S., Lei, S., Wu, S., Lei, S., Chen, X., Tan, L., Jian, W., Hongxu, Deng, F., et al. (2007) · Annals of Human Biology · doi:10.1080/03014460701275749 · Cited by 16
In vitro and in vivo effects of adiponectin on bone
Williams, G., Wang, Y., Callon, K. E., Watson, M., Lin, J., Lam, J. B. B., Costa, J. L., Orpe, A., Broom, N. D., Naot, D., et al. (2009) · Bone · doi:10.1016/j.bone.2009.01.033 · Cited by 11
Clarke, B. L. (2010) · Yearbook of Medicine · doi:10.1016/s0084-3873(10)79794-7 · Cited by 6
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
“Bone HG [12] 2013 Postmenopausal women with impaired fasting glucose or impaired glucose tolerance 59 Pioglitazon vs placebo”
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D., & Goulis, D. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00042 · Cited by 205
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka-Czernik, B. (2016) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
Sweeney, T. E., & Morton, J. M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.016 · Cited by 120
Metadata
- Authors
- Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G.
- Affiliations
- Helen Hayes Hospital (US)
- Takeda (United States) (US)
- Corresponding author
- Bone, Henry G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4691-4701
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2085155826
- Cited by
- 47
- References
- 53
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 2
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Takeda Pharmaceuticals North America
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- thiazolidinediones, bone mineral density, bone turnover, postmenopausal women, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, fracture, glycemic control, insulin sensitivity, fat mass, lumbar spine
- MeSH terms
- Pioglitazone, Aged, Bone and Bones, Bone Resorption, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Middle Aged, Prediabetic State, Biomarkers, Bone Density, Bone Remodeling, Postmenopause, Glucose Intolerance, Thiazolidinediones, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.